Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CTNM · as of Jun 8, 2026
Key Statistics
Explore Contineum Therapeutics, Inc. Class A Common Stock Data
ctnm stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 66.7%
The CTNM analyst consensus is Buy, based on ratings from 3 Wall Street analysts over the past 3 months. The average 12-month price target is $16.00, representing +39.25% upside from the current price of $11.49.
Competitors & Peers
ctnm competitorsCTNM
ACIU
ALDX
AMRN
ANRO
CADLStock Performance
Full HistoryAbout Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indic…
what is contineum therapeutics, inc. class a common stock · ctnm stock overview · contineum therapeutics, inc. class a common stock company profile · who is contineum therapeutics, inc. class a common stock ceo · ctnm NASDAQ · contineum therapeutics, inc. class a common stock headquarters · contineum therapeutics, inc. class a common stock business segments
About Stock Overview & Key Data
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 5, 2024. As of the latest trading session, CTNM stock price is $11.49, with a market capitalization of $429.6M. The stock has returned +156.47% over the past 12 months and +0.52% year-to-date.
According to 3 Wall Street analysts, the consensus rating for Contineum Therapeutics, Inc. Class A Common Stock stock is Buy, with an average 12-month price target of $16.00. In fiscal year 2025, Contineum Therapeutics, Inc. Class A Common Stock reported revenue of — and net income of -$60.0M. For detailed data — including Contineum Therapeutics, Inc. Class A Common Stock revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock price is $11.49. The stock is traded on NASDAQ under the ticker symbol CTNM. The 52-week range is $3.57 – $16.33.